Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 2CNS 1

Conditions

Pituitary Neoplasms 1Central Nervous System Neoplasms 1

Interventions

Proton Therapy 2pegvisomant 1lutetium Lu 177 dotatate 1entinostat 1Temozolomide 1Surveys and Questionnaires 1Rosiglitazone 1Radiation Dose Hypofractionation 1Protons 1Prednisone 1Photochemotherapy 1Octreotide 1Neuropsychological Tests 1Microarray Analysis 1Hydrocortisone 1Dihematoporphyrin Ether 1Dexamethasone 1DNA Methylation 1Clinical Laboratory Techniques 1Calcium Dobesilate 1Cabergoline 1Blood Specimen Collection 1Aminolevulinic Acid 190Y-octreotide, DOTA-Tyr(3)- 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pituitary Neoplasms × Rosiglitazone × CNS × Clear all
NCT00616642 2020-08-14

Rosiglitazone in Treating Patients With Pituitary Tumors

Jonsson Comprehensive Cancer Center

Phase 2 Terminated
1 enrolled 4 charts
CNSEndocrine

Pituitary Neoplasms, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡